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In vitro and in vivo activity of ML302F: a thioenolate
inhibitor of VIM-subfamily metallo β-lactamases
Jonathan W. Betts,a Lynette M. Phee,ab Muhd H. F. Abdul Momin,a
Klaus-Daniel Umland,c Jurgen Brem,c Christopher J. Schofieldc
and David W. Wareham*ab
The thioenol ML302F was recently identified as an inhibitor of class B metallo-β-lactamases (MBLs). We
assessed the activity of ML302F when combined with meropenem (MEM) against 31 carbapenem resistant
Gram-negative clinical isolates. Minimum inhibitory concentrations of MEM :ML302F were determined at
fixed ratios of 1 : 4 and 1 : 8 using strains producing variants of the clinically relevant VIM-like MBL. Toxicity
and efficacy in vivo was assessed in a Galleria mellonella invertebrate model against strains producing VIM-
1, VIM-2 and VIM-4 variants. At a fixed MEM :ML302F ratio of 1 : 8, 22/31 isolates were rendered either sus-
ceptible (MIC ≤ 2 mg L−1), or intermediate (MIC 4–8 mg L−1) to MEM. ML302F alone was not toxic at up to
80 mg kg−1 in G. mellonella and treatment with MEM 0.6 mg kg−1 :ML302F 4.8 mg kg−1 significantly
improved the survival of infected larvae. As ML302F was able to successfully restore susceptibility to resis-
tant strains both in vitro and in vivo it represents a structurally interesting inhibitor in the search for new
MBL inhibitors.
Introduction
The global dissemination of multi-drug resistant Gram-
negative bacteria has seriously limited antibiotic treatment
options. As few novel synthetic antimicrobials are in develop-
ment the challenge is to increase and protect the lifespan and
spectrum of existing compounds for as long as possible. This
is most important in the case of β-lactams (penicillins, cepha-
losporins, carbapenems) especially when resistance occurs
due to the acquisition and production of β-lactamases that
catalyse β-lactam hydrolysis.1 There are two distinct mecha-
nistic classes of β-lactamase – the nucleophilic serine
enzymes and the metallo β-lactamases (MBLs). Inhibitors of
the serine enzymes (clavulanic acid/tazobactam/avibactam)
have been developed and already applied clinically.2 However,
no such compounds have yet been developed to target
MBLs. The use of carbapenems such as ertapenem, imipenem
or meropenem (MEM) in combination with an effective
metallo-β-lactamase inhibitor, could prolong their lifespan as
well as increase their spectrum of use to carbapenemase pro-
ducing bacteria. Thus, there are ongoing efforts to develop
MBL inhibitors of suitable potency and breadth of selectivity
for clinical use.3 In the latter regard the ability to inhibit the
different subtypes of clinically relevant MBLs and apparently
rapidly emerging variants will likely be important.
The rhodanine ML302 was initially identified as a MBL
inhibitor in a high throughput screen and subsequently
characterised as a non-competitive inhibitor of class B (IMP,
VIM, NDM) metallo-β-lactamases in vitro.4 Recently the mech-
anism behind the apparent inhibition by ML302 was investi-
gated in crystallographic, NMR, and kinetic studies. These,
unexpectedly revealed that ML302 undergoes hydrolysis, to
generate the thioenol ML302F (Fig. 1). The thiol of ML302F
chelates the two zinc ions present in the active site of most
MBLs in a manner mimicking an intermediate in β-lactam
hydrolysis.5 In some cases the observed inhibition of MBLs
by ML302/ML302F combinations may involve ternary com-
plexes. In some instances ML302F is able to inhibit the
carbapenemase activity of MBLs at low μM concentrations
(IC50 VIM-2 0.30 μM) sufficient to restore the activity of
meropenem against MBL-producing strains.5
Neither ML302 nor ML302F have significant cytotoxicity
towards eukaryotic cells in tissue culture (>100 μM) but have
not yet been assessed in any animal model of antimicrobial
therapeutics. The wax moth caterpillar Galleria mellonella is
increasingly being used as a simple invertebrate model for
pre-clinical assessment of the efficacy, toxicity and pharmaco-
kinetics of antimicrobials.6–9 Here we report studies on the
activity of ML302F in combination with MEM against a col-
lection of carbapenem resistant clinical isolates (Pseudomo-
nas, Klebsiella, Enterobacter, Escherichia coli, Providencia)
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producing clinically relevant variants of the VIM (VIM-1/2/4)
MBL. Preferred ratios of MEM to ML302F required for syn-
ergy in vitro were determined and then used at a simulated
humanized pharmacokinetic dose in the treatment of G.
mellonella infected with carbapenem resistant P. aeruginosa,
K. pneumoniae and E. coli.
Results and discussion
The antimicrobial activities of MEM and ML302F alone and
in combination were assessed in vitro against 31 VIM-
producing clinical isolates. Synergy between MEM and
ML302F was first confirmed in checkerboard assays against
7/8 isolates tested (FICI ≤ 0.5). An MEM :ML302F ratio of 1 : 4
and 1 : 8 was found to be optimal resulting in a ≥4 fold
reduction in the MIC of MEM.
Thirty strains were either resistant (MIC > 8 mg L−1) or
had reduced susceptibility (MIC ≥ 4 mg L−1) to MEM alone
as judged by the European Committee on Antimicrobial Sus-
ceptibility (EUCAST) breakpoint criteria. One K. pneumoniae
isolate harbouring blaVIM-1 was deemed susceptible (MIC 1
mg L−1). ML302F had no antimicrobial activity alone at con-
centrations up to 512 mg L−1.
Using a fixed 1 : 8 ratio of MEM :ML302F in vitro suscepti-
bility to carbapenems was increased in 22/31 (70%) of the iso-
lates with 11 rendered susceptible (MIC ≤ 2 mg L−1) or inter-
mediate (MIC 4–8 mg L−1). For 9 isolates, the MIC of MEM
remained >8 mg L−1 (Table 1).
ML302F was non-toxic when administered to G. mellonella
by injection at doses up to 80 mg kg−1 (100% survival of all
larvae at 96 h). The inoculum required for staggered killing
of >50% of larvae by carbapenem resistant strains over 96 h
varied by species. The LD50 was <10
1, 105 and 104 CFU per
larvae for P. aeruginosa GR57, E. coli 98 and K. pneumoniae
respectively.
In treatment assays, survival of ML302F (4.8 mg kg−1)
treated larvae was similar to those given PBS for the treat-
ment of PA GR57, EC 98 and KP 120 infections. Monotherapy
with MEM (0.6 mg kg−1) was superior to either PBS and
ML302F (P < 0.0001), but the % survival was only 44%, 23%
and 69% versus strains EC 98, PA GR57 and KP 120, respectively.
The addition of ML302F to MEM significantly improved the
survival of infected larva (P < 0.0001) compared to MEM
alone, with survival rates of 69% (EC 98), 81% (PA GR57) and
98% (KP 120) at 96 (Fig. 2) and a relative risk for MEM-
ML302F versus MEM of 0.64, 0.28 and 0.70 for these isolates.
Experimental
Materials
Bacterial strains were from the collection of clinical isolates
held at Queen Mary University London. Species identification
was by analysis of MADLI-TOF mass spectrometry profiles
(Bruker) and MBL detection by PCR and sequencing of the
blaVIM gene Meropenem trihydrate was purchased from
Ranbaxy (UK) Limited (London, UK). ML302F was produced
within the Chemical Research Laboratories, Oxford University
Table 1 Minimum inhibitory concentrations (MICs) of meropenem
(MEM) with and without ML302F (1 : 8) versus multidrug-resistant Gram-
negative bacteria producing VIM carbapenemases
MBL Isolate
MIC (mg L−1)
FICIMEM MEM + ML302F
VIM-1 K. pneumoniae GR54 128 4 0.09
VIM-1 K. pneumoniae 177 1 1 1.02
VIM-1 P. stuartii 67 8 1 0.14
VIM-1 P. stuartii 70 8 1 0.14
VIM-2 P. aeruginosa 30 64 8 0.25
VIM-2 P. aeruginosa 47 32 1 0.05
VIM-2 P. aeruginosa 50 32 8 0.38
VIM-2 P. aeruginosa GR57 32 4 0.19
VIM-2 P. aeruginosa GR58 32 8 0.38
VIM-2 P. aeruginosa GR62 32 8 0.38
VIM-2 P. aeruginosa GR64 32 4 0.19
VIM-2 P. aeruginosa 3 (13) 64 8 0.25
VIM-2 P. aeruginosa 8 (13) 128 16 0.38
VIM-2 P. aeruginosa 9 (13) 128 16 0.38
VIM-2 P. aeruginosa 11 (13) 32 2 0.09
VIM-2 P. aeruginosa 6 (14) 128 16 0.38
VIM-2 P. aeruginosa 11 (14) 128 32 0.75
VIM-2 P. aeruginosa 12 (14) 128 32 0.75
VIM-2 P. aeruginosa 13 (14) 32 16 0.75
VIM-2 P. aeruginosa 14 (14) 64 2 0.06
VIM-2 P. aeruginosa 15 (14) 64 16 0.5
VIM-2 P. aeruginosa 16 (14) 64 16 0.5
VIM-2 P. aeruginosa 27 (14) 64 16 0.5
VIM-4 E. cloacae 102 32 4 0.19
VIM-4 E. coli 98 16 2 0.16
VIM-4 K. oxytoca 95 32 8 0.38
VIM-4 K. oxytoca 126 32 4 0.19
VIM-4 K. pneumoniae 101 32 2 0.09
VIM-4 K. pneumoniae 120 16 2 0.25
VIM-4 K. pneumoniae 128 4 1 0.27
VIM-4 K. pneumoniae 196 16 1 0.08
Fig. 1 Structures of (a) the thioenol ML302F, (b) the ‘parent’
rhodanine ML302, (c) outline mechanism for MBL catalysed β-lactam
hydrolysis as exemplified with meropenem (PDB ID: 4EYL), and (d) car-
toons based on a crystal structure of ML302F (PDB ID: 4PVO)
complexed with MBLs showing how the inhibitor mimics an enzyme-
intermediate/product complex.
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(Oxford, UK). All media were purchased from SigmaAldrich
(Dorset, UK).
Minimum inhibitory concentrations
Minimum inhibitory concentrations (MICs) of MEM (0–64
mg L−1) and ML302F (0–32 mg L−1) were determined by broth
microtiter dilution (BMD) in Mueller-Hinton 2 cation-
adjusted broth with a bacterial inocula of 105 colony forming
units (CFU) per well in accordance with Clinical Laboratory
Standards Institute (CLSI) guidance. Initial screening assays
were performed using eight Gram-negative isolates including
P. aeruginosa (VIM-2), Escherichia coli (VIM-4), Klebsiella
pneumoniae (VIM-4) and Providencia stuartii (VIM-1). K.
pneumoniae NCTC 9633 and P. aeruginosa ATCC 27853 were
used as MEM susceptible type strains to control BMD MIC
determinations.
The activity of ML302F in combination with MEM was
assessed in checkerboard assays with fractional inhibitory
concentration index (FICI) and MEM :ML302F ratio used to
quantify interactions.10 A FICI (MIC of MEM/ML302F + MIC
ML302F/MEM) of ≤0.5 was defined as synergy, a FICI of 0.5
to 4.0 as indifferent or additive, and values of >4.0 as
antagonistic. MICs for the MEM/ML302F combination strains
studied were determined at fixed MEM :ML302F ratios of 1 : 4
and 1 : 8 by BMD.
Toxicity assays
The in vivo toxicity of ML302F was assessed in the Galleria
mellonella wax moth larvae model using a simple live dead
ranking.11 Increasing doubling concentrations of ML302F (0
to 80 mg kg−1) were administered in 10 μl injections directly
into the hemocoel of ten larvae before incubation at 37 °C
for 96 h. Larvae were scored for mellonisation and movement
every 24 h, as live or dead. Larvae for all G. mellonella assays
were purchased from Livefood UK Ltd (Somerset, UK).
G. mellonella virulence assay
The bacterial inocula required for staggered killing (50%
lethal dose [LD50]) of G. mellonella by VIM producing isolates
over 96 h was determined using 10 larvae inoculated with
overnight cultures of E. coli EC98, K. pneumoniae KP120 and
P. aeruginosa PA GR57. Tenfold serial dilutions were made
from washed cultures, diluted in PBS and administered in 10
μl injections at final concentrations of 101–106 CFU per larvae
and incubated at 37 °C for 96 h. Larvae were scored as live or
dead every 24 h.
MEM/ML302F treatment assays
The activity of MEM and ML302F alone and in combination
were assessed using 16 G. mellonella larva as previously
described.12 Larvae were inoculated with P. aeruginosa GR57,
E. coli EC98 and K. pneumoniae KP120. In combination thera-
pies, a fixed ratio (1 : 8) of MEM :ML302F containing 0.6 mg
kg−1 of MEM8 and 4.8 mg kg−1 of ML302F was administered
in 10 μL injections to infected larvae. PBS injections (10 μL)
were used as both controls for no antimicrobial therapy and
inoculation injury.
Larvae were scored for survival over 96 h and kill curves
analysed by the log-rank test for trend. Relative risk (RR) of
survival between the different treatment arms was calculated
using Fisher's exact test with, two-tailed P-values of <0.05
considered statistically significant.
Conclusions
In combination with MEM at a 1 : 8 ratio ML302F was able to
restore susceptibility to MEM amongst VIM-producing
carbapenem resistant Enterobacteriaceae (CRE) and was
active in vivo in the G. mellonella larva invertebrate model of
CRE infection. ML302F was active against several clinically
relevant VIM variants. The combined results reveal that
ML302F is a structurally interesting MBL inhibitor active in
both cellular and animal models and should stimulate fur-
ther work on the synthesis and testing of ML302F analogues.
ML302F was derived from a rhodanine by hydrolysis. We are
well aware that as a class the rhodanines have a somewhat
chequered history with respect to their use as (potential)
Fig. 2 Treatment assays using meropenem (MEM), ML302F and a
1 : 8 (mg kg−1) combination of MEM + ML302F versus VIM-2 producing
Pseudomonas aeruginosa isolate GR57 (a) VIM-4 producing Escherichia
coli 98 (b) and Klebsiella pneumoniae 120 (c) over 96 h in Galleria
mellonella.
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pharmaceuticals.13,14 Furthermore, one may anticipate that the
development of thioenols as pharmaceuticals might be diffi-
cult due to their reactivity (e.g. due to oxidation). However, as
is well known the structures of many antibiotics do not fol-
low recent ‘normal’ paradigms for drug structures.15 This is
beautifully exemplified by the Class A serine β-lactamase
inhibitors (clavulanic acid, tazobactam, sulbactam) that are
widely used to extend penicillin and cephalosporin use.
These are themselves β-lactams which act as ‘mechanism
based’ inhibitors that undergo fragmentation on their target
β-lactamases to produce ester linked species that are stable
with respect to hydrolysis.15 The fact that rhodanines can
undergo hydrolysis (whether enzyme mediated or not in the
case of ML302/ML302F) to produce potent thioenol inhibitors
raises the question as to whether mechanism based MBL
inhibitors that are β-lactams which produce thioenol inhibi-
tors can be generated. In this regard the development of
modified carbapenems (one carbapenem, faropenem is in
clinical use)16 (Fig. 3) which have the potential to undergo
hydrolysis to produce thioenols that are MBL inhibitors may
be of interest.
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